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BACKGROUND: In many countries, decisions about
the public funding of drugs are preferentially
based on the results of randomized trials. For
truly rare diseases, such trials are not typically
available, and approaches by public payers are
highly variable. In view of this, a policy framework
intended to fairly evaluate these drugs was devel-
oped by the Drugs for Rare Diseases Working
Group (DRDWG) at the request of the Ontario
Public Drug Programs.
OBJECTIVE: To report the initial experience of applying
a novel evaluation framework to funding applications
for drugs for rare diseases.
METHODS: Retrospective observational cohort study.
MEASURES: Clinical effectiveness, costs, funding rec-
ommendations, funding approval.
KEY RESULTS: Between March 2008 and February
2013, eight drugs were evaluated using the DRDWG
framework. The estimated average annual drug cost
per patient ranged from 28,000 to 1,200,000 Cana-
dian dollars (CAD). For five drugs, full evaluations
were completed, specific funding recommendations
were made by the DRDWG, and funding was ap-
proved after risk-sharing agreements with the man-
ufacturers were negotiated. For two drugs, the
disease indications were determined to be ineligible
for consideration. For one drug, there was insuffi-
cient natural history data for the disease to provide a
basis for recommendation. For the five drugs fully
evaluated, 32 patients met the predefined eligibility
criteria for funding, and five were denied based on
predefined exclusion criteria.
CONCLUSIONS: The framework improved transparency
and consistency for evaluation and public funding of
drugs for rare diseases in Ontario. The evaluation
process will continue to be iteratively refined as feed-
back on actual versus expected clinical and economic
outcomes is incorporated.
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INTRODUCTION
In 2007, the Ontario Ministry of Health and Long-term
Care in the province of Ontario, Canada, established the
Drugs for Rare Diseases Working Group (DRDWG) to
develop an evidence-based evaluation framework to
inform funding decisions for drugs for rare diseases
(DRDs). Drug funding decisions made by public payers
usually take into consideration a drug’s effectiveness
(derived from randomized controlled studies) and its
cost-effectiveness. However, for truly rare diseases, it
may be difficult to conduct clinical trials of adequate
sample size and duration to rigorously assess a drug’s
effectiveness. In addition, DRDs are often very expen-
sive and, with little or no confirmatory data on their
effectiveness, are rarely found to be cost-effective.
However, a policy of not funding any of these drugs
on the basis of insufficient evidence and/or inefficient
use of public spending might be considered unreason-
able by the public.1 On the other hand, routinely
funding DRDs on a compassionate basis might also be
considered unfair.2 In a recent environmental scan, the
Canadian Agency for Drugs and Technologies in Health
identified both highly variable definitions of what
constitutes a rare disease and rapid expansion in
regulatory mechanisms to approve and incentivize
development of drugs for rare diseases internationally
over the past 20 years, but virtually no specific
reimbursement frameworks.3
In Canada, most health care is publicly funded and
managed at the provincial government level. In Ontario
(population 13 million), the Ontario Public Drug Programs
(OPDP) within the Ontario Ministry of Health & Long-term
Care oversees provincial drug expenditures. OPDP has an
annual budget of 4.5 billion Canadian dollars (CAD) and
provides drug funding for eligible program recipients.
Manufacturers apply to OPDP for public reimbursement
of their drugs under six different programs. The Committee
to Evaluate Drugs, an independent expert panel, advises the
OPDP on which drugs to fund based on clinical and cost-
effectiveness assessments of each individual drug product.
The OPDP Executive Officer, reporting to the Ontario
Minister of Health, considers the recommendation of the
Committee to Evaluate Drugs and makes the final funding
decision. Typically data from randomized trials is necessary
for the adequate evaluation and listing of new drug entities
on the OPDP formulary.
The Drugs for Rare Diseases Working Group (DRDWG)
was established in response to the 2007 recommendation by
the Committee to Evaluate Drugs against the public funding
of idursulfase for Hunter syndrome (mucopolysaccharidosis
II) due to insufficient evidence of effectiveness.4 Recognizing
the inherent challenges of gathering robust data for drugs for
rare diseases, the Executive Officer established the DRDWG
to investigate and develop a different policy mechanism for
the evaluation of these drugs.
The DRDWG initially consisted of nine members selected by
the Executive Officer: three representatives from the Ontario
Ministry of Health and Long-term Care (the Executive Officer
and two pharmacists), four current or previous members of the
Committee to Evaluate Drugs (two physicians, a pharmacist,
and a health economist), and two other physicians, one with
formal pharmacoeconomic training and the other an expert in
the treatment of inherited disorders of metabolism in children.
Several principles formed the basis of the policy development
process. First, the perspective would be that of a public payer
addressing requests for funding for a specific drug. Other
guiding precepts included respect for the principles of "account-
ability for reasonableness" of Daniels and Sabin,1 with the
expectation that the ideal policy product would be transparent,
consistent, address unique aspects of the treatment of a specific
rare condition while being adaptable to other dissimilar
conditions, and include an appeals process. This process has
been described previously, and a seven-step policy framework
based on the principles of evidence-based medicine and
epidemiological causality was developed, implemented, and
made publicly available (Table 1).5,6 The aim of this report is to
describe the initial experience using this framework to develop
funding recommendations for drug applications, and to examine
the subsequent effect on drug funding decisions and costs.
METHODS
Between March 2008 and February 2013, eight drugs were
identified as candidates for review by the DRDWG. We
reviewed the degree to which their evaluations conformed
to the seven-step evaluation process: 1. confirm that the
condition for treatment with the candidate drug is truly
“rare”; 2. understand the disease (usual history based on
best available evidence); 3. understand the potential value
of the candidate drug (based on best available evidence); 4.
model the potential clinical effectiveness of the candidate
drug; 5. evaluate cost implications and generate a funding
recommendation; 6. review the drug evaluation with disease
experts and stakeholders; and 7. assessment for re-evalua-
tion (Table 1). For the purposes of this report, two members
of the Working Group (WC and CS) collected the data from
evaluations to date, and these were assessed by all of the
authors. We also recorded the completeness of the estimates
of clinical effectiveness and cost for each drug, the
development of funding recommendations, and the results
of funding decisions by the Executive Officer. For drugs
approved for funding, the results of individual patient
funding decisions were also reviewed.
RESULTS
Of the eight drugs evaluated using the framework (Table 2),
six were for rare inherited metabolic enzyme deficiencies,
one for a malignancy, and two for uncommon idiopathic
conditions. The estimated average annual drug cost per
patient ranged from 28,000 to 1,200,000 CAD. Idursulfase
for Hunter syndrome, the first drug evaluated, was used to
iteratively develop the framework and is included in the
results. The other drugs and disease indications were:
alglucosidase for Pompe disease, miglustat for Niemann-
Pick disease type C, laronidase for mucopolysaccharidosis
Table 1. Evaluation Framework for Funding Drugs for Rare
Diseases
Step 1: Assess whether the drug is suitable for evaluation using the
framework
• Confirm that the disease condition is rare. Work to date supports a
definition of "rare" as an incidence rate below one in 150,000 (births
or new diagnoses per year).
• Consider whether there are adequately powered randomized
controlled trials that report on clinically relevant outcomes. Consider
whether the rarity of the disease prohibits conducting these trials.
Step 2: Review the natural history of the disease
• Gain an understanding of the underlying mechanism of the disease,
its presentation and diagnosis, its progression over time, and eventual
outcomes.
Step 3: Assess the potential effectiveness of the treatment
• Understand the mechanisms of action of the drug therapy.
• Using best available evidence, establish whether sufficient evidence
exists to support or suggest that the proposed therapy is likely to be
effective.
• Apply modified Bradford Hill criteria as required.
Step 4: Model the potential clinical effectiveness of the treatment
• Develop a disease model to estimate the effects of progression of the
disease with and without the treatment under evaluation.
Step 5: Evaluate cost and budget impact and generate funding
recommendation
• Cost-effectiveness is not a deciding factor. Affordability remains a
consideration in the final decision-making process.
• Make a funding recommendation. For positive funding
recommendations, develop funding criteria, including start, renewal,
and stop criteria.
Step 6: Review drug evaluation with experts and stakeholders
• Conduct validity exercises with experts where necessary.
• Communicate funding recommendation/decision to stakeholders.
Step 7: Reassessment
• Periodic re-evaluation of the drug review, including the disease
model and the funding criteria, as new data on the drug and/or disease
become available.
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I, galsulfase for mucopolysaccharidosis VI, vorinostat for
cutaneous T-cell lymphoma, canakinumab for cryopyrin-
associated periodic syndrome, and eculizumab for paroxys-
mal nocturnal hemoglobinuria. At each step of the
assessment, the members of the DRDWG came to a
consensus only after review of adequate data about both
the disease and drug. If a disease or drug failed to meet
criteria at any of the steps, it was considered unsuitable for
further evaluation using the framework.
Evaluation Process
Step 1. Confirm that the condition for treatment with the
candidate drug is truly “rare”
For each drug evaluation, the “rarity” of the
disease indication was carefully reviewed. Rarity
limits not only the ability to conduct adequately
powered randomized trials, but also understanding
of the disease's natural history, which may be
biased toward more severe variants of the disorder.
In addition, variability in the clinical phenotype of
a rare disease can make the selection of suitable
clinical outcomes extremely difficult and force
researchers to rely on surrogate outcomes of
uncertain validity. Often, the DRDWG experi-
enced some pressure to define an explicit thresh-
old. However, it was recognized that review under
this process, which potentially modeled clinical
effectiveness, could be error prone and should be
used exceptionally, not routinely. In addition, there
was consensus that the existence of a process for
evaluating drugs for rare diseases should not
diminish the motivation to conduct randomized
trials in conditions that were simply uncommon or
difficult to study (i.e., “best possible evidence”
should be required). The disease indications for six
Table 2. Drugs Evaluated Using the Drugs for Rare Diseases Working Group (DRDWG) Framework
Drug & Indication Evaluation
Date
DRDWG
Recommendation
Funding
Status
Price Average Dose &
Annual Drug
Cost Per Patient
Total Drug
Expenditures
Idursulfase:
Hunter Syndrome
Mar–Sep
2008
Re-evalua-
tion:
Early 2011
Fund with criteria EAP with
criteria
(May 2009)
$3,800 per
6 mg vial
0.5 mg/kg/week IV
20 kg child:
$400,000
70 kg adult:
$1,200,000
$8,614,945 (Jun
2009–Jun 2012)
Alglucosidase:
Adult & Infant-
onset Pompe
Disease
Nov 2008–Jul
2009
Re-evalua-
tion:
Jun–Sep 2011
Fund with criteria EAP with
criteria
(Jun 2009)
$840 per
50 mg vial
20 mg/kg/2 week
IV
Adult-onset
(70 kg):
$600,000
$16,861,408 (Jun
2009–Jun 2012)
Miglustat:
Niemann Pick,
Type C
Early 2010 Fund with criteria EAP with
criteria
(Apr 2010)
$109 per
100 mg
capsule
12+ years old: 200
mg 3x/day PO
under 12:100 mg/
day to 200 mg 3x/
day PO according
to BSA
$237,720
Approximately
$1,000,000 (Apr
2010–Jun 2012)
Laronidase:
MPS I
Oct 2010–Jun
2011
Fund with criteria IMD
Program with
criteria (Sep
2011)
$1,045 per
2.9 mg vial
0.58 mg/kg/week
IV
40 kg:$45,000
70 kg:$760,000
Approximately*
$19,000,000 (Jan
2007–Apr 2012)
Galsulfase:
MPS VI
Mar–Apr
2010
Re-evalua-
tion: Mar–
Sep2012
Do not fund
Unable to provide
recommendation
IMD
Program on
case-by-case
basis
$1,479
(USD) per
5 mg vial
1 mg/kg/week IV
20 kg:$300,000
70 kg:$1,000,000
Approximately*
$3,000,000 (Jul 2006–
Jun 2012)
Vorinostat: Cutaneous
T-cell
Lymphoma
Apr–Sep
2010
Standard CED review
Asked to reconsider &
DRDWG recommended
no funding due to lack
of QOL data
Not funded $75.50 per
100 mg
capsule
400 mg/day PO
$28,000 (based on
median treatment
duration of
147 days)
$0
Canakinumab:
Cryopyrin-associated
periodic syndrome
Sep 2010–
Jun2011
Fund with criteria EAP with
criteria
(Mar 2012)
$16,000
per 150 mg
vial
150 mg SC
every 8 weeks
$104,000
$0
Eculizumab:
Paroxysmal nocturnal
Hemoglobinuria
Sep 2009 Standard CED review
CED asked DRDWG
assistance to develop
model & funding
criteria
EAP with
criteria
(Sep 2011)
$6,743 per
300 mg
vial
600 mg weekly x 4
weeks;
900 mg on week 5
then
900 mg every
2 weeks IV
$530,000
$8,678,053 (Aug
2011–Jun 2012 )
All monetary amounts are given in CAD. *Includes compassionate funding for some patients prior to DRDWG recommendations
DRDWG Drugs for Rare Diseases Working Group, CAD Canadian Dollars, EAP Eexceptional Access Program, BSA body surface area, MPS
mucopolysaccharidosis, IMD Inherited Metabolic Diseases, USD US dollars, pt patient, CED Committee to Evaluate Drugs, QOL quality of life
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of the eight drugs reviewed were considered of
sufficient rarity towarrant evaluation: Hunter syndrome
(1.3:100,000 male live births), Pompe disease
(1:40,000 live births), Niemann-Pick type C (incidence
1:150,000), mucopolysaccharidosis I (1:50,000 live
births), mucopolysaccharidosis IV (1:700,000 live
births), and cryopyrin-associated periodic syndrome
(incidence 1:1,000,000). The disease indications for
two drugs (cutaneousT-cell lymphoma and paroxysmal
nocturnal hemoglobinuria) were considered ineligible
for further consideration under this framework, because
it was determined that the size of the available patient
population and the nature of the disease were amenable
to good-quality clinical trials to assess meaningful
endpoints, and thus should not be evaluated through a
revised policy framework based on lower levels of
evidence. These two drugs were referred for regular
review through the standard evaluation process of the
Committee toEvaluateDrugs,where standard evidence
from randomized trials is expected.
Step 2. Understand the disease
This step entails gaining an understanding of the basic
pathophysiology, natural history, and health effects of
the disease condition and the mechanism of action of
the candidate drug. This then allows for a critical
review of the actual or potential effects of the drug
treatment on the disease trajectory. Five of the six
eligible disease indications were considered to have
sufficient natural history information available to
understand the disease and to predict potential effects
from drug therapy. Insufficient information about the
natural history for mucopolysaccharidosis VI pre-
cluded modeling for this disease. As a result, the
DRDWG was unable to predict the nature and extent
of benefit that galsulfase could provide. In this case,
the paucity of natural history information and clinical
trial data on the drug’s efficacy made it impossible for
the DRDWG to render an evidence-informed funding
recommendation. The drug was rejected for funding
on this basis, with feedback to the manufacturer to
provide natural history data for a future resubmission.
Step 3. Understand the potential value of the candidate
drug
The theoretical value of the drug for the disease
indication is evaluated at this step. Although there was
some debate within the Working Group about the
specificity of canakinumab for cryopyrin-associated
periodic syndrome, ultimately all five drugs eligible
were considered to be of potential clinical value.
Step 4. Model the potential clinical effectiveness of the
candidate drug
Using the data identified in steps 2 and 3, clinical
effectiveness can be estimated using modeling
techniques that include estimates of the magnitude
and the variability of treatment effects, with
explicit acknowledgment of the limitations of the
data and techniques used. When possible, the
DRDWG used Bayesian-style decision modeling
to synthesize data of variable quality from
different sources. Typically, the prior probabilities
for the most clinically relevant outcomes were
drawn from studies of the natural history of the
disease in question, and the impact of the new
drug on these outcomes over time was estimated
based first on the best available evidence of
effectiveness from clinical studies; modeling for
time frames beyond that was informed by the
clinical studies.
The example of idursulfase for Hunter disease has
been described previously.7 In brief, a Markov
model of the disease course was developed with
input from the DRDWG and validation by
external clinical experts. Disease epidemiology
was extracted from available case series data, with
use of informed expert opinion when necessary.
Cycle lengths were 6 months, and a lifetime
horizon was used, with a maximum age at death
set at 80 years. Disease progression was described
from diagnosis to musculoskeletal symptoms to
respiratory symptoms to cardiovascular symptoms
to cardiorespiratory failure. It was assumed that
patients would progress sequentially through these
health states, and the rate of progression was
estimated from natural history data. A set of
transition probabilities was determined, allowing
estimation of the average life expectancy of
cohorts of Hunter disease patients based on their
age and current health status. The potential
benefits of idursulfase based on available clinical
data were then also included, as were life years
gained with this intervention. Based on this
modeling of clinical effectiveness, the DRDWG
concluded that idursulfase could reduce the like-
lihood of development of musculoskeletal and
respiratory symptoms, but there was neither
evidence nor biologic plausibility to suggest an
impact on neurodegeneration or on the progres-
sion of cardiac disease and cardiorespiratory
failure. The model informed the recommendations
of the DRDWG, and the Executive Officer
endorsed a policy of considering requests for
reimbursement of idursulfase for patients with
confirmed diagnosis of Hunter disease who are
aged 6 years or older and who have no or minimal
non-progressive neurocognitive impairment.
All five drugs that were not excluded based on
evaluation in steps 1–3 of the framework next
underwent similar modeling of clinical effective-
ness. The models were used to predict the
potential benefit or lack of benefit of the drug
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treatments, thereby informing funding recommen-
dations and clinical eligibility criteria.
Step 5. Evaluate cost implications and generate a funding
recommendation
All five drugs eligible for step 4were evaluated for cost
implications, including budget impact. As it was
obvious that the cost per quality-adjusted life year for
all five drugs was beyond conventional funding
thresholds, formal pharmacoeconomic analyses were
not performed. In addition, specific reimbursement
guidelines, including clinical criteria for initiation,
continuation, and termination of funding, were devel-
oped for all five drugs. The Executive Officer agreed
with all five funding recommendations, and these
drugs are now publicly funded in Ontario according to
clinical criteria developed by the DRDWG.5
Step 6. Review the drug evaluation with disease experts
and stakeholders
Input from external disease experts was sought in steps
1 to 5 as required. Upon completion of the evaluation,
outcomes of the review, including the data and
assumptions used to inform the clinical and economic
predictive modeling, were shared with physician and
patient stakeholder groups to identify areas of dis-
agreement or error. This also provided stakeholders
with the opportunity to engage in the DRDWG
process, which should facilitate acceptance of funding
policy conclusions. Formal stakeholder consultations
were conducted with physicians, patients, and industry
representatives for idursulfase, the first drug reviewed
through the framework. For miglustat, a face validity
exercise was conducted with experts. For the other
three recommendations, the reimbursement guidelines
were circulated to physician and patient groups, and
when necessary, reimbursement guidelines were
revisited based on feedback.
Step 7. Reassessment
New information regarding disease incidence, natural
history, and the effectiveness or cost of drug therapy
may trigger re-evaluation at this step. Three of the
drugs completing full evaluation have undergone
reassessment (idursulfase, alglucosidase, and
miglustat). In each case, the reassessment found that
revisions of the initial funding guidelines were not
required based on new information that had emerged
since the initial review.
Drugs that Completed Evaluation
Five drugs underwent full framework evaluation, including
Markov modeling of clinical effectiveness. When there
were recommendations for drug cost reimbursement for
individual patients, these included highly specific criteria
for treatment initiation, mandatory requirements for contin-
uation of funding, and criteria for discontinuing treatment
based on futility. Based on the recommended eligibility and
exclusion criteria for fundable conditions, all five drugs
were subsequently approved for funding by the Executive
Officer of the Ontario Public Drug Programs after risk-
sharing agreements were made with the manufacturers.
Drugs that did not Complete Evaluation
Two disease indications were considered ineligible for
review under the framework: cutaneous T-cell lymphoma
and paroxysmal nocturnal hemoglobinuria. The manufac-
turer of vorinostat did not pursue reimbursement through
the standard Committee to Evaluate Drugs evaluation
process. Eculizumab was subsequently reviewed, and it
was recommended that eculizumab not be funded. Howev-
er, the Committee also indicated that there was likely a
subset of patients for whom eculizumab might be of benefit
and that this patient subgroup was not well defined in the
data provided by the manufacturer. As a result, OPDP
engaged an expert committee that included two members of
the DRDWG to develop a predictive model to help estimate
the potential benefit of eculizumab in modifying disease
outcomes; funding guidelines were subsequently developed.
For galsulfase, the OPDP Executive Officer decided to
provide funding on a case-by-case basis, on compassionate
grounds.
Funding Policy Results
For the five drugs recommended for funding based on these
criteria, 32 patients met the eligibility criteria and received
the drug for ongoing treatment. However, at least one of
these patients met criteria determining futility of the
treatment, and the drug was no longer funded for this
patient. Five patients have been denied funding for these
drugs based on predefined exclusion criteria (Table 2).
DISCUSSION
This evaluation framework has been a useful guide for the
evaluation of drugs for rare diseases in Ontario, providing a
more consistent and transparent process. The framework
incorporates principles of decision making informed by the
best possible evidence, epidemiological causality (Brad-
ford-Hill’s criteria), and Bayesian modeling of clinical
effectiveness. Modeling of effectiveness has been a very
important component of the evaluation and often informs
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not only the specific clinical criteria for funding recom-
mendations (i.e., eligibility criteria, futility rules, stopping
criteria), but also the criteria for risk-sharing agreements
with industry, in order to reinforce these criteria. We feel
that by accepting a model of effectiveness based on a
candidate drug’s potential effects on disease natural history,
this evaluation framework implicitly reflects an ethical basis
through principles analogous to “accountability for reason-
ableness.”
However, the evaluation framework has several limita-
tions. Evaluations require dedicated and often protracted
efforts by a group of experts and stakeholders. So far, full
evaluations have been limited to diseases that might be
considered “ultra-rare.” Specific definitions of “rare” have
been deliberately avoided, and each disease of interest has
been evaluated case-by-case, based on a consensus opinion
on whether randomized trials with pragmatic endpoints
could be completed within a reasonable time frame and
with reasonable effort and cost. Such decisions must
consider the prevalence, severity, and clinical heterogeneity
of the disease, as well as the potential efficacy of the
candidate drug. Care has been taken to avoid creating a
perception that the DRDWG evaluation framework is an
opportunity to avoid the difficulty and expense of pragmatic
randomized clinical trials when these are possible. An
expert in Markov modeling (DC) has been essential to the
formulation of funding recommendations. However, such
modeling requires credible information about the natural
history of the candidate disease, and for “ultra-ultra rare”
diseases, this may not be feasible and limits the scope of
evaluation.
The evaluation framework described represents a com-
promise to address the dilemma of inadequate trial evidence
upon which to make funding policy decisions about drugs
for rare diseases. It is designed to retain fidelity to the
evidence-informed evaluation process upon which drug
reimbursement is based in Ontario, but with application to
exceptional circumstances, without digression to a policy of
universal compassionate funding without consideration of
reasonable eligibility criteria, futility rules, and stopping
rules that can be gleaned within reason from available
evidence. The evaluation process allows for re-evaluation of
funding recommendations as new data arises, some of
which may be produced by comparing the results of funding
decisions made with those predicted by the disease models.
There should not be major barriers to adapting this type of
evaluation framework outside Canada, among both public
and private payers, provided that adequate committed
expertise is available and transparency remains a high
priority. The evaluation process has been—and continues to
be—refined iteratively with each drug evaluation. Ultimate-
ly, further observation and analysis will be required to
determine the value of this evaluation process. In particular,
the passage of time will allow comparison of predicted
clinical and economic outcomes from the modeled versus
the real-world clinical and economic outcomes. While the
results of real-world outcomes can theoretically be fed back
into the model to improve future decisions, the reality of
ultra-rare diseases means that it will take several years to
obtain improved information from one province alone.
Future collaborations toward a similar iterative policy
framework might expedite knowledge creation across
Canada, or even internationally.
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